PubMed Health⌕ Search

PubMed · 3316247

Changes in heterogeneous nuclear RNP core polypeptide complements during the cell cycle.

Abstract

Mammalian heterogeneous nuclear RNP (hnRNP) subcomplexes are shown to be comprised of 14-17 basic A and B core group polypeptides (chrp) when subjected to two-dimensional immunoblot analysis. These proteins are normally confined to the nucleus but are distributed throughout the cell during mitosis. However, not all of the 17 protein spots are observed for all stages of the cell cycle. HeLa cell populations have been synchronized and the basic hnRNP core protein complement examined during S, G2, mitosis, and G1. During cell division several distinct chrp polypeptide species at 35 and 37 kD appear, while another of 37 kD and a chrp of 38 kD are diminished. These altered chrp complements are not due to any effects induced by thymidine treatment but appear to be physiological changes in the chrp polypeptide modification state. The new charge isomers found during mitosis are not the result of selective phosphorylation of the chrp polypeptides. However the nature of the modifications has yet to be determined. The mitosis-specific modified forms of the chrp polypeptides are found in the cytoplasmic fraction derived from mitotic cell populations. When this fraction is centrifuged upon sucrose density gradients the modified chrp polypeptides sediment from 30-200S in a distribution similar to that of hnRNP complexes isolated from the nuclei of randomly dividing cell populations. RNase digestion experiments indicate that the general substructure of the RNA/protein complexes in mitotic cell cytoplasm is similar to that of nuclear hnRNP isolated from unsynchronized cells or tissue.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G P Leser, T E Martin. 1987. Changes in heterogeneous nuclear RNP core polypeptide complements during the cell cycle.. https://doi.org/10.1083/jcb.105.5.2083

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗

Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.

Lymphoproliferative disease (LPD) is a complication of congenital and acquired immunodeficiency states. There are a number of treatment options for LPD arising after haematopoietic stem cell or solid organ transplantation including reduction of immunosuppression, targeted therapies, such as the anti-CD20 monoclonal antibody, rituximab, and EBV specific cytotoxic lymphocytes. Treatment of LPD in children with congenital immunodeficiency syndromes remains unsatisfactory and is associated with a high mortality rate. We recently managed an infant found to have polymorphic LPD concurrent with X-linked severe combined immunodeficiency (SCID). Haematopoietic stem cell transplantation (HSCT) had to be deferred because of progressive LPD. Treatment with rituximab resulted in regression of the LPD following which the patient received a 5/6 HLA matched umbilical cord blood (UCB) transplant. The patient remains well 20 months following transplantation. Rituximab treatment may have a useful role in the control of LPD associated with congenital immunodeficiency prior to HSCT.

Antibodies, Monoclonal↗

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab.

Antibodies, Monoclonal↗